Amantadine-induced livedo reticularis occurring during treatment of chronic hepatitis C
Corresponding Author
E Minutilli
Department of Surgical Sciences and
* Corresponding author, Department of Surgical Sciences, Catholic University of Sacred Heart, Largo A. Gemelli, 8–00168, Rome, Italy, tel./fax +39 (0)6 6638909; E-mail: [email protected]Search for more papers by this authorM Pompili
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorG Pelecca
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorGL Rapaccini
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorG Gasbarrini
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorCorresponding Author
E Minutilli
Department of Surgical Sciences and
* Corresponding author, Department of Surgical Sciences, Catholic University of Sacred Heart, Largo A. Gemelli, 8–00168, Rome, Italy, tel./fax +39 (0)6 6638909; E-mail: [email protected]Search for more papers by this authorM Pompili
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorG Pelecca
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorGL Rapaccini
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorG Gasbarrini
Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy,
Search for more papers by this authorDOI: 10.1111/j.1468-3083.2008.02613.x
References
- 1 Sladden MJ, Nicolaou N, Johnston GA, Hutchinson PE. Livedo reticularis induced by amantadine. Br J Dermatol 2003; 149: 656–658.
- 2 Hayes BB, Cook-Norris RH, Miller JL, Rodriguez A, Zic JA. Amantadine-induced livedo reticularis: a report of two cases. J Drugs Dermatol 2006; 5: 288–289.
- 3 Salgado JC, Gutknecht DR. A reticular rash. Am J Med 2006; 119: 577–578.
- 4 Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005; 25: 3312–3322.
- 5 Shulman LM, Minagar A, Sharma K, Weiner WJ. Amantadine-induced peripheral neuropathy. Neurology 1999; 53: 1862–1865.
- 6 Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon non responsive chronic hepatitis C. Hepatology 2000; 32: 630–634.
- 7 Ciancio A, Picciotto A, Giordanino C et al . A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther 2006; 24: 1079–1086.
- 8 Mihm U, Grigorian N, Welsch C et al . Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir Ther 2006; 11: 507–519.
- 9 Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rekela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007; 52: 732–736.
Citing Literature
